P. Trojer

发表

The key to development: interpreting the histone code?

D. Reinberg, R. Margueron, P. Trojer, 2005, Current opinion in genetics & development.

Virtual Screening and Biological Characterization of Novel Histone Arginine Methyltransferase PRMT1 Inhibitors

P. Trojer, W. Sippl, René Meier, 2009, ChemMedChem.

Small molecule inhibitors of histone arginine methyltransferases: homology modeling, molecular docking, binding mode analysis, and biological evaluations.

A. Tramontano, A. Mai, P. Trojer, 2007, Journal of medicinal chemistry.

A novel arginine methyltransferase inhibitor with cellular activity.

P. Trojer, W. Sippl, R. Schüle, 2007, Bioorganic & medicinal chemistry letters.

Target-based approach to inhibitors of histone arginine methyltransferases.

P. Trojer, W. Sippl, R. Schüle, 2007, Journal of medicinal chemistry.

A quantitative atlas of histone modification signatures from human cancer cells

Peter A. DiMaggio, B. Garcia, Yibin Kang, 2013, Epigenetics & Chromatin.

HdaA, a Major Class 2 Histone Deacetylase of Aspergillus nidulans, Affects Growth under Conditions of Oxidative Stress

P. Trojer, M. Tribus, G. Brosch, 2005, Eukaryotic Cell.

Histone Methylation Modifiers in Medical Therapeutics

P. Trojer, 2016 .

An Alternative Approach to ChIP-Seq Normalization Enables Detection of Genome-Wide Changes in Histone H3 Lysine 27 Trimethylation upon EZH2 Inhibition

Feng Zhao, Suchit Jhunjhunwala, Charles Hatton, 2016, PloS one.

Mammalian SWI/SNF-A Subunit BAF250/ARID1 Is an E3 Ubiquitin Ligase That Targets Histone H2B

P. Trojer, J. Treisman, N. Tanese, 2010, Molecular and Cellular Biology.

Merkel cell polyomavirus activates LSD1-mediated blockade of non-canonical BAF to regulate transformation and tumorigenesis

M. Washburn, Jingwei Cheng, J. Decaprio, 2020, Nature Cell Biology.

Small molecule targeting of chromatin writers in cancer

P. Trojer, A. Conery, J. Rocnik, 2021, Nature Chemical Biology.

Discovery and Optimization of Tetramethylpiperidinyl Benzamides as Inhibitors of EZH2.

P. Trojer, R. Cummings, L. Bergeron, 2014, ACS medicinal chemistry letters.

Characterization of two putative histone deacetylase genes from Aspergillus nidulans.

P. Trojer, J. Walton, G. Brosch, 2000, Biochimica et biophysica acta.

Modulation of EZH2 expression in T cells improves efficacy of anti–CTLA-4 therapy

P. Sharma, P. Trojer, Hao Zhao, 2018, The Journal of clinical investigation.

An inhibitor-resistant histone deacetylase in the plant pathogenic fungus Cochliobolus carbonum.

P. Trojer, J. Walton, G. Brosch, 2001, Biochemistry.

MPN-343: The BET Inhibitor Pelabresib Decreases Inflammatory Cytokines, Improves Bone Marrow Fibrosis and Function, and Demonstrates Clinical Response Irrespective of Mutation Status in Myelofibrosis Patients in the Phase 2 MANIFEST Trial

P. Trojer, M. Salama, S. Verstovsek, 2021 .

Dynamic Histone H1 Isotype 4 Methylation and Demethylation by Histone Lysine Methyltransferase G9a/KMT1C and the Jumonji Domain-containing JMJD2/KDM4 Proteins*S⃞

D. Reinberg, T. Jenuwein, P. Trojer, 2009, Journal of Biological Chemistry.

Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymp

Jon R. Wilson, A. Good, P. Trojer, 2016, Journal of medicinal chemistry.

Histone H2B Monoubiquitination Functions Cooperatively with FACT to Regulate Elongation by RNA Polymerase II

D. Reinberg, A. Shilatifard, S. Mandal, 2006, Cell.

Characterization of Inhibitor-Resistant Histone Deacetylase Activity in Plant-Pathogenic Fungi

Dipnath Baidyaroy, Jonathan D. Walton, P. Trojer, 2002, Eukaryotic Cell.

Plant-Pathogenic Fungi Histone Deacetylase Activity in Characterization of Inhibitor-Resistant

P. Trojer, J. Walton, G. Brosch, 2002 .

A Novel Motif in Fungal Class 1 Histone Deacetylases Is Essential for Growth and Development of Aspergillus

P. Trojer, M. Tribus, Ingo Bauer, 2010, Molecular biology of the cell.

Pharmacological Inhibition of the Histone Lysine Demethylase KDM1A Suppresses the Growth of Multiple Acute Myeloid Leukemia Subtypes.

Thomas V. O'brien, P. Trojer, D. Stokoe, 2016, Cancer research.

A KDM5 Inhibitor Increases Global H3K4 Trimethylation Occupancy and Enhances the Biological Efficacy of 5-Aza-2'-Deoxycytidine.

S. Baylin, P. Trojer, D. Arnott, 2018, Cancer research.

Identification of potent, selective KDM5 inhibitors.

P. Trojer, P. Sandy, Y. Leblanc, 2016, Bioorganic & medicinal chemistry letters.

An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells.

P. Trojer, E. Jackson, D. Arnott, 2016, Nature chemical biology.

Demethylation of H3K27 Regulates Polycomb Recruitment and H2A Ubiquitination

Min Gyu Lee, D. Reinberg, R. Shiekhattar, 2007, Science.

Targeting histone lysine methylation in cancer.

P. Trojer, J. Mcgrath, 2015, Pharmacology & therapeutics.

KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs.

P. Park, Kwok-Kin Wong, P. Trojer, 2013, The Journal of clinical investigation.

Histone Lysine Demethylases and Their Impact on Epigenetics

Danny Reinberg, D. Reinberg, P. Trojer, 2006, Cell.

L3MBTL2 protein acts in concert with PcG protein-mediated monoubiquitination of H2A to establish a repressive chromatin structure.

D. Reinberg, Xiaoqin Xu, P. Farnham, 2011, Molecular cell.

Beyond histone methyl-lysine binding: How malignant brain tumor (MBT) protein L3MBTL1 impacts chromatin structure

Danny Reinberg, D. Reinberg, P. Trojer, 2008, Cell cycle.

L3MBTL1, a Histone-Methylation-Dependent Chromatin Lock

D. Reinberg, P. Trojer, H. Erdjument-Bromage, 2007, Cell.

Methods to identify and functionally analyze factors that specifically recognize histone lysine methylation.

D. Reinberg, P. Trojer, R. Sims, 2006, Methods.

JMJD 6 Is a Histone Arginine Demethylase

Min Gyu Lee, D. Reinberg, R. Shiekhattar, 2022 .

Design, Synthesis, and Pharmacological Evaluation of Second Generation EZH2 Inhibitors with Long Residence Time.

P. Trojer, R. Sims, Shilpi Arora, 2020, ACS medicinal chemistry letters.

EZH2 inhibition results in genome-wide PRC2 redistribution

P. Trojer, G. Tucker-Kellogg, Barbara Bryant, 2019, bioRxiv.

EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation.

P. Trojer, Shilpi Arora, R. Cummings, 2014, Chemistry & biology.

The Target of the NSD Family of Histone Lysine Methyltransferases Depends on the Nature of the Substrate

D. Reinberg, P. Trojer, O. Gozani, 2009, The Journal of Biological Chemistry.

Facultative heterochromatin: is there a distinctive molecular signature?

D. Reinberg, P. Trojer, 2007, Molecular cell.

Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.

E. Chan, P. Trojer, P. Sandy, 2013, Chemistry & biology.

Chromatin in the nuclear landscape.

D. Reinberg, R. Margueron, P. Trojer, 2010, Cold Spring Harbor symposia on quantitative biology.

A phase 1b/2 study of CPI-1205, a small molecule inhibitor of EZH2, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration resistant prostate cancer (mCRPC).

P. Trojer, E. Antonarakis, A. Senderowicz, 2018 .

Mass Spectrometric Quantification of Histone Post-translational Modifications by a Hybrid Chemical Labeling Method

Jun Liang, A. Masselot, P. Trojer, 2015, Molecular & Cellular Proteomics.

De Novo Peptide Design and Experimental Validation of Histone Methyltransferase Inhibitors

Christodoulos A. Floudas, Benjamin A. Garcia, Athanassios Giannis, 2014, PloS one.

Design and evaluation of 1,7-naphthyridones as novel KDM5 inhibitors.

Jun Liang, P. Trojer, R. Cummings, 2016, Bioorganic & medicinal chemistry letters.

Identification and Characterization of a Novel Nuclear Protein Complex Involved in Nuclear Hormone Receptor-mediated Gene Regulation*

P. Trojer, H. Samuels, T. Neubert, 2009, Journal of Biological Chemistry.

Histone deacetylases in fungi: novel members, new facts.

P. Trojer, M. Tribus, G. Brosch, 2003, Nucleic Acids Research.

From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitors.

Jun Liang, P. Trojer, Y. Ran, 2017, Bioorganic & medicinal chemistry letters.

Lead optimization of a pyrazolo[1,5-a]pyrimidin-7(4H)-one scaffold to identify potent, selective and orally bioavailable KDM5 inhibitors suitable for in vivo biological studies.

Jun Liang, P. Trojer, R. Cummings, 2016, Bioorganic & medicinal chemistry letters.

Complement component C8γ is expressed in human fetal and adult kidney independent of C8α

P. Trojer, B. Redl, P. Merschak, 1999 .

Histone methyltransferases in Aspergillus nidulans: evidence for a novel enzyme with a unique substrate specificity.

P. Trojer, Ingo Bauer, G. Brosch, 2004, Biochemistry.

MANIFEST-2, a Global, Phase 3, Randomized, Double-Blind, Active-Control Study of CPI-0610 and Ruxolitinib Vs. Placebo and Ruxolitinib in JAK-Inhibitor-Naive Myelofibrosis Patients

P. Trojer, S. Verstovsek, C. Harrison, 2020, Blood.

Discovery, design, and synthesis of indole-based EZH2 inhibitors.

A. Good, P. Trojer, R. Cummings, 2015, Bioorganic & medicinal chemistry letters.

Identification and characterization of second-generation EZH2 inhibitors with extended residence times and improved biological activity

P. Trojer, R. Sims, Shilpi Arora, 2021, The Journal of biological chemistry.

Merkel cell polyomavirus activates LSD1-mediated blockade of non-canonical BAF to regulate transformation and tumorigenesis

M. Washburn, Jingwei Cheng, J. Decaprio, 2020, Nature Cell Biology.

Design and Synthesis of Styrenylcyclopropylamine LSD1 Inhibitors.

A. Good, P. Trojer, R. Cummings, 2020, ACS medicinal chemistry letters.

Epigenetics: Disrupting histone lysine methylation.

P. Trojer, 2015, Nature chemical biology.

A quantitative atlas of histone modification signatures from human cancer cells

Peter A. DiMaggio, B. Garcia, Yibin Kang, 2013, Epigenetics & Chromatin.

Targeting BET Bromodomains in Cancer

P. Trojer, 2022, Annual Review of Cancer Biology.

A phase II study of cpi-0610, a bromodomain and extraterminal protein inhibitor (BETi) alone or with ruxolitinib (RUX), in patients with myelofibrosis (MF).

P. Trojer, S. Verstovsek, R. Hoffman, 2019, Journal of Clinical Oncology.

MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or "Add-on" to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis

B. Leber, P. Trojer, S. Verstovsek, 2019, Blood.

A gateway to study protein lysine methylation.

D. Reinberg, P. Trojer, 2008, Nature chemical biology.

KDM2B controls tumorigenesis in pancreatic cancer via Polycomb-dependent and -independent transcriptional programs

Nabeel, P. Park, P. Trojer, 2012 .

L3MBTL2 protein acts in concert with PcG protein-mediated monoubiquitination of H2A to establish a repressive chromatin structure.

D. Reinberg, Xiaoqin Xu, P. Farnham, 2011, Molecular cell.

Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.

E. Chan, P. Trojer, P. Sandy, 2013, Chemistry & biology.

A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma

I. Flinn, P. Trojer, M. Maris, 2022, Cancer research communications.